Daratumumab
- Generic Name
- Daratumumab
- Brand Names
- Darzalex, Darzalex Faspro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 945721-28-8
- Unique Ingredient Identifier
- 4Z63YK6E0E
- Background
Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind.
...
- Indication
Daratumumab is indicated as an intravenous injection alone or in combination with other medications for the treatment of multiple myeloma. It is available as a combination product with hyaluronidase for the treatment of adults with multiple myeloma as monotherapy or combination therapy and light chain amyloidosis in combination with other drugs.
- Associated Conditions
- Multiple Myeloma (MM), Primary Amyloidosis, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Associated Therapies
- -
Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- University Hospital, Lille
- Target Recruit Count
- 74
- Registration Number
- NCT05572229
- Locations
- ๐ซ๐ท
Chu Amiens - Hopital Sud, Amiens, France
๐ซ๐ทChru Angers, Angers, France
๐ซ๐ทCh D'Avignon, Avignon, France
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 15
- Registration Number
- NCT05556616
- Locations
- ๐บ๐ธ
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธGabrail Cancer Center Research, Canton, Ohio, United States
๐บ๐ธScripps Health, San Diego, California, United States
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1590
- Registration Number
- NCT05552222
- Locations
- ๐จ๐ณ
The Second Xiangya Hospital of Central South Hospital, Changsha, China
๐จ๐ณThe First Affliated Hospital Of Nanchang University, Nanchang, China
๐ฆ๐นSCRI CCCIT gem GmbH, Salzburg, Austria
Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.
- Conditions
- Interventions
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2022-09-02
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 140
- Registration Number
- NCT05527340
- Locations
- ๐ช๐ธ
Hospital Universitario de Canarias, La Laguna, Spain
๐ช๐ธHospital Universitario 12 de Octubre, Madrid, Spain
๐ช๐ธClรญnica Universidad de Navarra, Pamplona, Spain
Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)
- First Posted Date
- 2022-08-03
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Alfred Chung, MD
- Target Recruit Count
- 46
- Registration Number
- NCT05486481
- Locations
- ๐บ๐ธ
University of California, San Francisco, San Francisco, California, United States
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
- Conditions
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 810
- Registration Number
- NCT05455320
- Locations
- ๐บ๐ธ
University of Kansas, Westwood, Kansas, United States
๐บ๐ธThe Ohio State University Wexner Medical Center - James Cancer Hospital, Columbus, Ohio, United States
๐บ๐ธOhioHealth, Columbus, Ohio, United States
A Study of Daratumumab
- Conditions
- Interventions
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 500
- Registration Number
- NCT05438043
- Locations
- ๐บ๐ธ
University of Miami Sylvester Cancer Center, Miami, Florida, United States
๐บ๐ธBarnes-jewish Hospital, Saint Louis, Missouri, United States
๐ง๐ชZNA Stuivenberg, Antwerpen, Belgium
COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
- Conditions
- Interventions
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 80
- Registration Number
- NCT05434689
- Locations
- ๐บ๐ธ
Duke University, Durham, North Carolina, United States
๐บ๐ธUniversity of Wisconsin, Madison, Wisconsin, United States
๐บ๐ธOregon Health and Science University, Portland, Oregon, United States
Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM
- Conditions
- Interventions
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Registration Number
- NCT05408026
Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders
- Conditions
- Interventions
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Tianjin Medical University General Hospital
- Target Recruit Count
- 135
- Registration Number
- NCT05403138
- Locations
- ๐จ๐ณ
Tianjin Medical University General Hospital, Tianjin, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.